Our venture capital fund focuses investments on early-stage life sciences companies looking to improve people’s outcomes with cancer.

Recent News

aiProteins_Final_logo300
08/08/2023

AI Proteins Strengthens Leadership with Appointment of Noah D. Beerman as Chief Executive Officer and Industry Leader Mark J. Alles as Chairman of the Board of Directors

READ MORE
Logo-Geneoscopy-400
08/03/2023

Closing the Gap: Why Healthcare Needs More Gender Diversity in Leadership

READ MORE
SimpleRose-logo
07/20/2023

Startup Exit Awards 2023: Supercomputer startup SimpleRose raises $23M to bring its technology to market

READ MORE
C4-logo-400
07/17/2023

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
NextRNA-Logo-FullColor-400
07/10/2023

Q&A with Rory Johnson, PhD

READ MORE
C4-logo-400
07/05/2023

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

READ MORE
SimpleRose-logo
06/21/2023

Small box. Big ambitions

READ MORE
NextRNA-Logo-FullColor-400
06/21/2023

Q&A with Susan Carpenter, PhD

READ MORE
C4-logo-400
06/20/2023

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

READ MORE

PORTFOLIO HIGHLIGHTS

WUGEN Logo
White C4 Therapeutics logo
Geneoscopy logo
NextRNA Logo
CareVet Logo
microbial-logo-header300